About BRAINAURORA-B Company

We are a veteran player in the digital therapy (“digital therapy”) market for cognitive impairment in China. According to Frost & Sullivan, we are the first company in China to combine brain science with advanced artificial intelligence (“AI”) technology to develop medical-grade digital therapy products for cognitive impairment. Our product pipeline covers the assessment and intervention of a wide range of cognitive disorders induced by vascular diseases, neurodegenerative diseases, mental disorders, and developmental defects in children. According to Frost & Sullivan, our core product is the first digital therapy product for cognitive impairment in China to receive regulatory approval. As a witness to our breakthrough achievements, we published the clinical trial results of the Brain Function Information Management Platform Software System (“System”) in the authoritative peer-reviewed journal “Alzheimer's & Dementia” (“A & D Journal”) for clinical research on cognitive impairment in May 2019. According to Frost & Sullivan, the paper confirmed the efficacy of digital therapy for non-demented vascular cognitive impairment (“VCIND”) for the first time in the world through evidence-based data from randomized controlled clinical trials. We are also deeply involved in the release of the first four expert consensus in the field of digital therapy in China. According to Frost & Sullivan's data, in March 2023, we co-wrote the “Chinese Expert Consensus on Cognitive Digital Therapy (2023)”. This article is the first time in China that systematically defines digital therapy for cognitive impairment, and has won us wide recognition from top hospitals and medical professionals in China. We believe that our market position and expertise in digital therapy research and development set a high barrier to entry for potential competitors.